Subscribe
Contact Us
About Us
Advertise
Home
News
News from MM&M
Off the Wire
Newsletters
PMD Profiles
Agency Creative Showcase
Publication Connection
PMD Marketplace
Careers
About Us
Additional Resources
MM&M
MM&M Jobs
MAHF
Voi Consulting
Advertise
Subscribe
Get Listed
Additional Resources
RSS
|
Login
|
Register
Merger
Facet Biotech Stockholders Reject Biogen Idec Tender Offer
December 17, 2009
The company will continue to pursue other opportunities
Silence Therapeutics to Merge with Intradigm Corp
December 16, 2009
Merger to Create Leading RNAi Therapeutics Company
Biogen Idec Stands Ready to Close Its $17.50 Per Share All-Cash Tender Offer for Facet Biotech
December 14, 2009
Biogen Idec Reminds Stockholders to Tender Their Shares by December 16, 2009
Pfizer And Wyeth Become One: Working Together For A Healthier World
October 16, 2009
Establishes and Expands Leadership in Human, Animal and Consumer Health
BioSante Pharmaceuticals and Cell Genesys Announce Final Exchange Ratio for Merger
September 22, 2009
Exchange Ratio Fixed at 0.1828
Biogen Idec Commences Tender Offer for Facet Biotech
September 21, 2009
Offers to Acquire All Outstanding Shares of Facet for $14.50 Per Share in Cash
Noven and Hisamitsu Enter into Definitive Merger Agreement
July 14, 2009
Hisamitsu to Commence All-Cash Tender Offer for 100% of Noven Shares
CombinatoRx and Neuromed Sign Merger Agreement
July 01, 2009
Merger to Create a Sustainable Biotechnology Company
Latest News
Portola Pharmaceuticals Announces Senior Management and Board Changes
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Most Popular
Most Emailed
Most Recent
Columbia Laboratories Enters into Purchase and Collaboration Agreement with Watson Pharmaceuticals for Progesterone Franchise
FDA Approves Exalgo Extended-Release Tablets
Astellas Pharma Inc. Commences Tender Offer to Acquire All Outstanding Shares of OSI Pharmaceuticals for $52 per Share in Cash
Transdel Pharmaceuticals Appoints Terry Nida as Chief Business Officer
CSL Behring Receives FDA Approval of Hizentra™
Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Pfizer And Medivation Announce Results From Two Phase 3 Studies In Dimebon (latrepirdine*) Alzheimer's Disease Clinical Development Program
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
Astellas Pharma Inc. Offers to Acquire OSI Pharmaceuticals for $52.00 Per Share in Cash
Novo Nordisk Receives FDA Approval for Norditropin(R) FlexPro(R) for Growth Hormone Treatment
FDA Advisory Committee Recommends Approval Of XIFAXAN® (rifaximin) Tablets, 550 Mg for Maintenance of Remission of Hepatic Encephalopathy
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Portola Pharmaceuticals Announces Senior Management and Board Changes
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Lilly to Acquire European Rights to Pfizer Animal Health Assets
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Portola Pharmaceuticals Announces Senior Management and Board Changes
Neoprobe Announces Successful Meeting on Lymphoseek Phase 3 Results
Pfizer Discontinues A Phase 3 Study Of Figitumumab In Previously Treated Patients With Advanced Non-Small Cell Lung Cancer
Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech
Abbott Receives U.S. FDA Approval for New Cataract Multifocal Intraocular Lens
Affymax® Receives $5 Million Milestone Payment on Initiation of Phase 3 Clinical Trials for Hematide in Japan
Alun Malone Joins Millennium Laboratories As New Business Development Executive
Lilly to Acquire European Rights to Pfizer Animal Health Assets
CSL Behring Receives FDA Approval of Hizentra™
EKR Therapeutics Appoints John Bailye as Interim President & Chief Executive Officer
Popular Topics
Acquisition
Agency
Animal Health
Biopharmaceutical
Biotech
Business
Clinical Management
Collaboration
Marketing & Communications
Medical Device
Medical Equipment
Merger
New Company
New Hire
New Hires
Personnel
Pharmaceutical
Pharmaceutical Marketplace
Pharmaceutical Products
Pipeline
Product Acquisition
Product Launch
Product Promotion
Regulatory
Research & Development